- Home
- CKPT vs PFD Comparison
CKPT vs PFD Comparison
Compare CKPT & PFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- PFD
- Stock Information
- Founded
- CKPT 2014
- PFD 1990
- Country
- CKPT United States
- PFD United States
- Employees
- CKPT N/A
- PFD N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- PFD Investment Managers
- Sector
- CKPT Health Care
- PFD Finance
- Exchange
- CKPT Nasdaq
- PFD Nasdaq
- Market Cap
- CKPT 151.9M
- PFD 145.7M
- IPO Year
- CKPT 2017
- PFD N/A
- Fundamental
- Price
- CKPT $3.00
- PFD $11.43
- Analyst Decision
- CKPT Strong Buy
- PFD
- Analyst Count
- CKPT 2
- PFD 0
- Target Price
- CKPT $13.50
- PFD N/A
- AVG Volume (30 Days)
- CKPT 998.1K
- PFD 33.2K
- Earning Date
- CKPT 11-12-2024
- PFD 01-01-0001
- Dividend Yield
- CKPT N/A
- PFD 6.30%
- EPS Growth
- CKPT N/A
- PFD N/A
- EPS
- CKPT N/A
- PFD N/A
- Revenue
- CKPT $47,000.00
- PFD N/A
- Revenue This Year
- CKPT N/A
- PFD N/A
- Revenue Next Year
- CKPT $172,016.02
- PFD N/A
- P/E Ratio
- CKPT N/A
- PFD N/A
- Revenue Growth
- CKPT N/A
- PFD N/A
- 52 Week Low
- CKPT $1.38
- PFD $8.53
- 52 Week High
- CKPT $4.50
- PFD $11.18
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- PFD 57.29
- Support Level
- CKPT $3.07
- PFD $11.12
- Resistance Level
- CKPT $3.42
- PFD $11.48
- Average True Range (ATR)
- CKPT 0.21
- PFD 0.19
- MACD
- CKPT -0.03
- PFD 0.03
- Stochastic Oscillator
- CKPT 4.94
- PFD 86.27
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.